[Vasoactive intestinal peptide (VIP): specific receptors and adenylate cyclase activation in a human prolactin-secreting pituitary tumor].
Receptors for the Vasoactive Intestinal Peptide (VIP) were characterized in particles enriched in plasma membranes obtained from a human prolactin-secreting pituiatry tumor. Native VIP inhibited competitively the binding of 125I-VIP to the particles and stimulated cyclic AMP production; both these effects were observed at concentrations of VIP as low as 10(-11)-10(-10) M, which are compatible with VIP concentrations in the hypothalamopituitary portal blood.
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000328:Adult; D002462:Cell Membrane / Q000378:metabolism; D004789:Enzyme Activation; D005768:Gastrointestinal Hormones / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008297:Male; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000503:physiopathology*; D011388:Prolactin / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism* / Q000494:pharmacology
D005768:Gastrointestinal Hormones; D011956:Receptors, Cell Surface; D014660:Vasoactive Intestinal Peptide; D011388:Prolactin; D000262:Adenylyl Cyclases
Vasoactive intestinal peptide (VIP): recépteurs specifiques et activation de l'adenylate cyclase dans une tumeur hypophysaire humaine à prolactine.